Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil
- PMID: 28476048
- DOI: 10.1097/ICO.0000000000001209
Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil
Abstract
Purpose: To report the safety and efficacy of descemetorhexis without grafting as a primary intervention in Fuchs dystrophy, and the use of a ROCK inhibitor, ripasudil as a salvage agent in failing cases.
Methods: Twelve eyes of 11 patients underwent central descemetorhexis not exceeding 4 mm. All had Fuchs dystrophy-producing visual symptoms, requesting intervention. Exclusion criteria were a peripheral endothelial cell count <1000 and central edema. Corneal clearance and visual parameters were recorded monthly until corneal clearance was observed, then at intervals of 6 months. Cases failing to clear by month 2 were considered for salvage treatment. This consisted of treatment with 1 of 2 formulations of Rho-associated kinase inhibitor eye drops. Endothelial keratoplasty was planned as the final salvage procedure in unsuccessful cases.
Results: Nine of 12 eyes cleared spontaneously between 2 and 6 months. One eye failed to clear by month 5 and topical Y-27632 was administered, without success. Endothelial keratoplasty was performed. In 2 eyes, healing stalled at 3 and 2 months. In both cases, topical ripasudil administered 6 times a day for 2 weeks resulted in complete corneal clearance. In cases achieving corneal clearance, best spectacle corrected visual acuity improved from a mean of 0.26 to 0.125 (logMAR) with subjective improvement in quality of vision.
Conclusions: In Fuchs dystrophy with visual degradation due to central guttae, descemetorhexis without grafting is a viable procedure for visual rehabilitation. Careful patient selection is required, but the advent of topical ripasudil as a salvage agent suggests that a broader application of the surgery may be possible. Further study into the use of this agent is now needed.
Comment in
-
ROCK Inhibitor (Ripasudil) as Coadjuvant After Descemetorhexis Without an Endothelial Graft.Cornea. 2017 Dec;36(12):e38-e40. doi: 10.1097/ICO.0000000000001381. Cornea. 2017. PMID: 28922333 No abstract available.
-
Reply.Cornea. 2017 Dec;36(12):e40-e41. doi: 10.1097/ICO.0000000000001380. Cornea. 2017. PMID: 28957981 No abstract available.
-
Reply.Cornea. 2018 Apr;37(4):e21-e22. doi: 10.1097/ICO.0000000000001529. Cornea. 2018. PMID: 29377844 No abstract available.
-
Descemetorhexis Without Endothelial Keratoplasty (DWEK): Proposal for Nomenclature Standardization.Cornea. 2018 Apr;37(4):e20-e21. doi: 10.1097/ICO.0000000000001528. Cornea. 2018. PMID: 29384812 No abstract available.
Similar articles
-
Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study.Cornea. 2021 Mar 1;40(3):320-326. doi: 10.1097/ICO.0000000000002437. Cornea. 2021. PMID: 32740006
-
Use of Topical Rho Kinase Inhibitors in the Treatment of Fuchs Dystrophy After Descemet Stripping Only.Cornea. 2019 May;38(5):529-534. doi: 10.1097/ICO.0000000000001883. Cornea. 2019. PMID: 30720541 Clinical Trial.
-
Descemet's stripping without endothelial keratoplasty.Curr Opin Ophthalmol. 2019 Jul;30(4):275-285. doi: 10.1097/ICU.0000000000000579. Curr Opin Ophthalmol. 2019. PMID: 31033737 Review.
-
In vivo confocal microscopy findings after Descemet stripping only with and without topical ripasudil supplementation in Fuchs endothelial dystrophy.Can J Ophthalmol. 2024 Dec;59(6):e682-e690. doi: 10.1016/j.jcjo.2024.02.016. Epub 2024 Mar 16. Can J Ophthalmol. 2024. PMID: 38503406
-
Descemetorhexis Without Graft Placement for the Treatment of Fuchs Endothelial Dystrophy: Preliminary Results and Review of the Literature.Cornea. 2017 Jun;36(6):637-641. doi: 10.1097/ICO.0000000000001202. Cornea. 2017. PMID: 28410355 Review.
Cited by
-
Case report: The use of netarsudil to improve corneal edema after laser peripheral iridotomy and Descemet's membrane endothelial keratoplasty.Am J Ophthalmol Case Rep. 2021 Apr 14;22:101087. doi: 10.1016/j.ajoc.2021.101087. eCollection 2021 Jun. Am J Ophthalmol Case Rep. 2021. PMID: 33997467 Free PMC article.
-
The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery.Transl Vis Sci Technol. 2021 Apr 1;10(4):18. doi: 10.1167/tvst.10.4.18. Transl Vis Sci Technol. 2021. PMID: 34003995 Free PMC article.
-
Hemi-Ultrathin Descemet Stripping Automated Endothelial Keratoplasty (Hemi-UT-DSAEK) Using Pediatric Donor Corneas: A Case Series.J Clin Med. 2023 Aug 22;12(17):5442. doi: 10.3390/jcm12175442. J Clin Med. 2023. PMID: 37685508 Free PMC article.
-
Transcription factor 4 promotes increased corneal endothelial cellular migration by altering microtubules in Fuchs endothelial corneal dystrophy.Sci Rep. 2024 May 4;14(1):10276. doi: 10.1038/s41598-024-61170-8. Sci Rep. 2024. PMID: 38704483 Free PMC article.
-
Increased Corneal Endothelial Cell Migration in Fuchs Endothelial Corneal Dystrophy: A Live Cell Imaging Study.Ophthalmol Sci. 2021 Mar 9;1(1):100006. doi: 10.1016/j.xops.2021.100006. eCollection 2021 Mar. Ophthalmol Sci. 2021. PMID: 36246012 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical